Memphasys, an Australian-listed company (ASX: MEM), initially specialised in proprietary electrophoresis and polymer membrane technology. Their primary focus was on the development of the Felix™ device, utilising this technology to facilitate the separation of sperm from semen. Collaborating with Distinguished Emeritus Laureate Professor John Aitken and his team at the Priority Research Centre for Reproductive Science at the University of Newcastle, Australia, the Felix™ device emerged as their inaugural product.
Subsequently, Memphasys strategically shifted its business development towards the artificial reproduction and fertility market, deepening its research collaboration with Professor John Aitken and the University of Newcastle team. Presently, a dedicated group of seven researchers at the University of Newcastle is engaged in advancing devices, media, and point-of-care diagnostic products within the realms of human and animal reproduction and fertility.
The Felix™ device, specialising in sperm separation technology, has transitioned into commercial production and is available for sale in early access countries, including India, Canada, and New Zealand. Memphasys is actively conducting clinical studies and preparing regulatory certifications in China and Australia, underscoring their commitment to advancing reproductive science technologies.
